rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
|
0.900 |
GeneticVariation
|
BEFREE |
Thus, while our results support the conclusion that the Met918Thr substitution is responsible for MEN2B, they suggest that the substrate specificity of the RET kinase does not interfere with its normal role in the development of the kidneys and enteric nervous system.
|
10675330 |
2000 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
C |
0.900 |
CausalMutation
|
CLINVAR |
A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.
|
10679286 |
2000 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
|
0.900 |
GeneticVariation
|
BEFREE |
Mutation analysis of exon 16 of the RET proto-oncogene revealed germline M918T and thus, a molecular diagnosis of multiple endocrine neoplasia type 2B (MEN 2B).
|
10369718 |
1999 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
C |
0.900 |
CausalMutation
|
CLINVAR |
Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
|
10445857 |
1999 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
|
0.900 |
GeneticVariation
|
BEFREE |
MEN2B is caused by a specific mutation (Met918-->Thr) in the RET receptor tyrosine kinase.
|
10023663 |
1999 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
C |
0.900 |
CausalMutation
|
CLINVAR |
Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
|
9242375 |
1997 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
|
0.900 |
GeneticVariation
|
BEFREE |
They are represented by the Met918Thr substitution (exon 16) typical of Multiple Endocrine Neoplasia type 2B (MEN2B) and, to a lesser extent, by nucleotide changes occurring at one of five critical cysteine residues (exons 10 and 11) typical of MEN type 2A (MEN2A).
|
9191060 |
1997 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
|
0.900 |
GeneticVariation
|
UNIPROT |
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
|
8918855 |
1996 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
C |
0.900 |
CausalMutation
|
CLINVAR |
Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome).
|
8880581 |
1996 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
C |
0.900 |
CausalMutation
|
CLINVAR |
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
|
7824936 |
1995 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
C |
0.900 |
GeneticVariation
|
CLINVAR |
RET activation by germline MEN2A and MEN2B mutations.
|
8570194 |
1995 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
C |
0.900 |
CausalMutation
|
CLINVAR |
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
|
7906866 |
1994 |
rs74799832
|
|
Multiple Endocrine Neoplasia Type 2b
|
C |
0.900 |
CausalMutation
|
CLINVAR |
Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.
|
7906417 |
1994 |